Product Description: Elenestinib (BLU-263) is an orally active inhibitor of Tyrosine kinase with an IC50 of 0.2 nM for KIT D816V. Elenestinib minimally penetrates the blood-brain barrier. Elenestinib can be used in the study of systemic mastocytosis[1][2].
Applications: Cancer-Kinase/protease
Formula: C27H29FN10O
References: [1]Dave N, et al. Safety and pharmacokinetics of BLU-263, a next-generation KIT inhibitor, in healthy volunteers[C]//Cancer Res (AACR Annual Meeting Abstracts). 2021, 122./[2]Chifotides HT, et al. SOHO State of the Art Update and Next Questions: Current and Emerging Therapies for Systemic Mastocytosis. Clin Lymphoma Myeloma Leuk. 2024 Jun 25:S2152-2650(24)00239-8.
CAS Number: 2505078-08-8
Molecular Weight: 528.58
Compound Purity: 98.82
Research Area: Cancer
Solubility: DMSO : 125 mg/mL (ultrasonic)
Target: c-Kit
Deutsch
English
